Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of “Buy” from Analysts

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has been given a consensus recommendation of “Buy” by the nine brokerages that are presently covering the stock, MarketBeat reports. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $39.86.

A number of analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $45.00 target price on shares of Oruka Therapeutics in a research note on Friday, February 7th. Wedbush reiterated an “outperform” rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Finally, Wolfe Research began coverage on Oruka Therapeutics in a research report on Tuesday, February 4th. They set an “outperform” rating and a $20.00 target price for the company.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of ORKA. JPMorgan Chase & Co. acquired a new stake in Oruka Therapeutics during the 4th quarter valued at $54,000. AlphaCentric Advisors LLC acquired a new stake in shares of Oruka Therapeutics in the fourth quarter valued at $119,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Oruka Therapeutics in the fourth quarter valued at about $144,000. Squarepoint Ops LLC acquired a new position in Oruka Therapeutics during the 4th quarter worth about $236,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in Oruka Therapeutics during the 4th quarter worth about $303,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Trading Down 2.3 %

Shares of ORKA stock opened at $11.02 on Friday. The firm has a fifty day simple moving average of $15.62. The firm has a market cap of $385.70 million, a PE ratio of -1.76 and a beta of 0.77. Oruka Therapeutics has a 52-week low of $10.61 and a 52-week high of $53.88.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.